A Phase 1 interventional study of DWP14012 and Placebo in Healthy, sponsored by Daewoong Pharmaceutical Co. LTD.. Completed at 1 site in Korea, Republic of. Open to male participants aged 19 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-04-25.
Sponsored by Daewoong Pharmaceutical Co. LTD. · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This is a dose block-randomized, double-blind, placebo- and active-controlled, single and multiple dosing, dose-escalation clinical phase 1 trial to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of DWP14012 after oral administration in healthy male volunteers.
Daewoong Pharmaceutical Co. LTD. is the lead sponsor of 200 studies on the registry; 33 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
DWP14012 Amg, tablets, orally, single dose administration
Drug: DWP14012 · Drug: Placebo
DWP14012 Bmg, tablets, orally, single dose administration
Drug: DWP14012 · Drug: Placebo
DWP14012 Cmg, tablets, orally, single dose administration
Drug: DWP14012 · Drug: Placebo
DWP14012 Dmg, tablets, orally, single dose administration
Drug: DWP14012 · Drug: Placebo
DWP14012 Emg, tablets, orally, single dose administration
Drug: DWP14012 · Drug: Placebo
DWP14012 Emg, tablets, orally, single dose administration
Drug: DWP14012 · Drug: Placebo
DWP14012 placebo-matching tablets, Active-control placebo-matching tablets, orally, single dose administration
Drug: Placebo
Nexium® tablets, orally, single dose administration
Drug: Placebo · Drug: Esomeprazole
DWP14012 Amg, tablets, orally, repeated dose administration(for 7days)
Drug: DWP14012 · Drug: Placebo
DWP14012 Bmg, tablets, orally, repeated dose administration(for 7days)
Drug: DWP14012 · Drug: Placebo
DWP14012 Cmg, tablets, orally, repeated dose administration(for 7days)
Drug: DWP14012 · Drug: Placebo
DWP14012 placebo-matching tablets, Active-control placebo-matching tablets, orally, repeated dose administration(for 7days)
Drug: Placebo
Nexium®, orally, repeated dose administration(for 7days)
Drug: Placebo · Drug: Esomeprazole
DWP14012 Dmg, tablets, orally, repeated dose administration(for 7days)
Drug: DWP14012 · Drug: Placebo
DWP14012 tablets
DWP14012 placebo-matching tablets, Active control placebo-matching tablets
Nexium®
Number and percentage of Participants With Adverse Events (AE)
All AE standardized using MedDRA was assessed by investigator using the protocol defined grading system. Intensity was categorized as mild, moderate adn severe.
Time frame: Day -2(Randomization) to Day 11~18(Post-study visit)
Number and percentage of Participants With Adverse Drug Reactions (ADR)
An adverse drug reaction (ADR) is an injury caused by taking an investigational product.
Time frame: Day -2(Randomization) to Day 11~18(Post-study visit)
Number of Participants With Clinically Significant Vital Sign findings
Blood pressure, pulse and body temperature were tested. The Average, Median, Standard Deviation, Min, Max values will be calculated to assess the safety/tolerability.
Time frame: Day -2(Randomization) to Day 11~18(Post-study visit)
Number of Participants With Clinically Significant Electrocardiogram(12-lead ECG) findings
Ventricular rate, RR interval, PR interval, QRS duration, QTcB and QTcF were recorded. The results of 12-lead ECG will be categorized Normal/Abnormal NCS(No clinically significant)/Abnormal CS(clinically significant).
Time frame: Day -2(Randomization) to Day 11~18(Post-study visit)
Number of Participants With Clinically Significant Laboratory results
Hematology, Blood chemistry, Coagulation and Urinalysis were tested. The Average, Median, Standard Deviation, Min, Max values will be calculated to assess the safety/tolerability.
Time frame: Day -2(Randomization) to Day 11~18(Post-study visit)
Cmax: Maximum concentration of DWP14012
in single ascending dose cohort
Time frame: 0(pre-dose), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, 24, 36, and 48 hours
Cmax,ss: Maximum concentration of DWP14012 at steady state
in multiple ascending dose cohort
Time frame: 0(pre-dose), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, 24h, Day 3-6 pre-dose, Day 7 pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, 24, 36, and 48 hours
Cmin,ss: Minimum concentration of DWP14012 at steady state
in multiple ascending dose cohort
Time frame: 0(pre-dose), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, 24h, Day 3-6 pre-dose, Day 7 pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, 24, 36, and 48 hours
Tmax: Time of maximum concentration
in single ascending dose cohort
Time frame: 0(pre-dose), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, 24, 36, and 48 hours
Tmax,ss: Time of maximum concentration at steady state
in multiple ascending dose cohort
Time frame: 0(pre-dose), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, 24h, Day 3-6 pre-dose, Day 7 pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, 24, 36, and 48 hours
AUClast: Area under the plasma concentration-time curve from time 0 to 48hours
in single ascending dose cohort
Time frame: 0(pre-dose), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, 24, 36, and 48 hours
AUCinf: Area under the plasma concentration-time curve from time 0 to infinity
in single ascending dose cohort
Time frame: 0(pre-dose), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, 24, 36, and 48 hours
AUCtau: Area under the plasma concentration-time curve from time 0 to tau(dosing interval)
in multiple ascending dose cohort
Time frame: 0(pre-dose), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, 24h, Day 3-6 pre-dose, Day 7 pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, 24, 36, and 48 hours
T1/2: Elimination half-life
in single ascending dose cohort
Time frame: 0(pre-dose), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, 24, 36, and 48 hours
T1/2: Elimination half-life
in multiple ascending dose cohort
Time frame: 0(pre-dose), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, 24h, Day 3-6 pre-dose, Day 7 pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, 24, 36, and 48 hours
Percentage of total time that the intragastric pH was above 4
After single administration of the investigational products, 24hr gastric pH monitoring started.
Time frame: Day 1
Percentage of total time that the intragastric pH was above 4
After multiple administration of the investigational products, 24hr gastric pH monitoring started.
Time frame: Day 7
Serum gastrin concentration profile
Time frame: Day -2(Randomization) to Day 11~18(Post-study visit)
Ran from Mar 2016 to primary completion in Feb 2017, 11 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Fexuprazan
Daewoong Pharmaceutical Co. LTD. →